1. What Happened? Hanmi Science H1 2025 Earnings Analysis
Hanmi Science recorded sales of KRW 670.4 billion and operating profit of KRW 61.7 billion in the first half of 2025, representing a decrease of 47.7% and 37.7%, respectively, compared to the same period last year. Declining sales in the pharmaceutical distribution sector and weak performance in the healthcare business were the main causes.
2. Why Did This Happen? Analyzing the Reasons for the Decline
- Weak Pharmaceutical Distribution: Sales declined significantly due to decreased sales volume of major products.
- Struggling Healthcare Business: Continued poor performance due to intensified market competition and changing consumer demand.
- Management Disputes: Ongoing management disputes among shareholders have negatively impacted investor sentiment.
3. What’s Next? Future Outlook and Investment Strategies
In the short term, uncertainty is expected to persist due to the weak earnings and management issues. However, Hanmi Pharmaceutical’s pipeline development performance and new business initiatives could serve as mid- to long-term growth drivers.
4. What Should Investors Do? Action Plan
- Monitor Earnings Recovery and New Business Performance: Continuously monitor whether the pharmaceutical distribution sector recovers and the growth potential of new businesses.
- Observe Management Issue Resolution: Pay close attention to the resolution of management disputes and the stabilization of corporate governance.
- Analyze the Impact of Macroeconomic Variables: Analyze the impact of macroeconomic variables such as exchange rates, interest rates, and oil prices, and incorporate them into investment strategies.